Recently, Chia Tai Tianqing Pharmaceutical Group (Red Sun Pharmaceutical) announced that its core product, Xuebijing Injection, has been successfully included in the ‘National Reimbursement Drug List (NRDL) 2023 Edition’ for basic medical insurance, work-related injury insurance, and maternity insurance. This inclusion signifies national recognition of the product’s clinical value, safety, and cost-effectiveness, and is expected to significantly enhance its market accessibility and patient utilization.Xuebijing Injection is a proprietary Chinese herbal injection developed by Red Sun Pharmaceutical, primarily used to treat sepsis and multiple organ dysfunction syndrome associated with severe infections. In recent years, the product has demonstrated strong efficacy and safety in multiple clinical studies and was included in China’s national COVID-19 treatment guidelines for managing severe and critical cases. Its addition to the NRDL will not only reduce patients’ financial burden but also promote broader adoption across healthcare institutions nationwide.The company stated it will actively support the implementation of the new reimbursement policy, strengthen quality control, and enhance academic promotion to ensure stable supply and continued clinical value. Industry experts believe this inclusion will provide a new growth driver for Red Sun Pharmaceutical and reflects the government’s ongoing support for innovation in traditional Chinese medicine.
近日，红日药业发布公告称，其核心产品血必净注射液成功被纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2023年版）》。这一举措标志着该产品在临床价值、安全性和经济性方面获得国家层面的认可，有望显著提升其市场可及性与患者使用率。血必净注射液是红日药业自主研发的中药注射剂，主要用于治疗脓毒症、多器官功能障碍综合征等重症感染相关疾病。近年来，该产品在多项临床研究中展现出良好的疗效与安全性，并在新冠疫情期间被纳入国家诊疗方案，用于重型、危重型患者的救治。此次纳入医保目录，不仅有助于减轻患者用药负担，也将进一步推动产品在各级医疗机构的广泛应用。红日药业表示，公司将积极配合医保政策落地，加强生产质量控制和学术推广，确保产品稳定供应并持续提升临床价值。业内人士分析认为，医保目录的纳入将为红日药业带来新的增长动力，同时也体现了国家对中医药创新成果的支持与鼓励。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/461.html